cas 253315-11-6|| where to buy 2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)pyrimidine-5-carboxylic acid

Product Name:2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)pyrimidine-5-carboxylic acid

IUPAC Name:2-{4-[(tert-butoxy)carbonyl]piperazin-1-yl}pyrimidine-5-carboxylic acid

Packing Unit	Available Stock	Price($)
CM335238-100mg	in stock	Ĳůů
CM335238-250mg	in stock	ȃƓƓ
CM335238-1g	in stock	ŹŹů
CM335238-5g	1-2 Weeks	ȃȃȃȃ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Additional Notes

Verification code*

refresh

: CAS NO:253315-11-6; Molecular Formula:C14H20N4O4; Melting Point:-; Smiles Code:O=C(O)C1=CN=C(N2CCN(C(OC(C)(C)C)=O)CC2)N=C1; Density:

: Catalog Number:CM335238; Molecular Weight:308.33; Boiling Point:; MDL No:; Storage:

: Piperazines; Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Avapritinib; Blueprint Medicines announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe.  AYVAKYT was designed to potently and selectively target KIT D816V, the primary underlying driver of the disease.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.